Markets WB starts VistaGen Therapeutics at OP; fair value estimate $7 William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing... August 28, 2019